Hysingla ER (Hydrocodone Bitartrate) Patent Expiration, LOE Window & CMS Spending

Hysingla ER (Hydrocodone Bitartrate) by Knoa: FDA Orange Book LOE 2031-12-21, 1 AB generics, $20.7M 2024 CMS Part D & Medicaid spend, and 14 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorKnoa
FDA Application & PathwayN206627 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-12-21
Orange Book Patents (*PED Extensions)19 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$20.7M
2024 Medicare Part D Spend$18.5M
2024 Medicaid Spend$2.2M
Reported Wholesale Price Change (CA SB 17)14 WAC filings (max 441.7% 2-yr change)